Mark Stejbach

VP & Chief Commercial Officer, TENGION INC.

Companies

IndiviorBoard member Jan 7, 2026 to now¹
Flexion TherapeuticsBoard member Sep 14, 2016 to Nov 19, 2021²
AlkermesChief Commercial Officer Mar 5, 2012 to Mar 5, 2018³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Indivior INDV27,087 shares⁴$910.7K at $33.62May 13, 2026
Flexion Therapeutics0 shares⁵Nov 19, 2021

As of each latest filing. The line shows shares held over time.

Recent filings

May 13, 2026Granted 6,518 shares of Indivior⁴
Jan 26, 2026Granted 3,722 shares of Indivior⁶
Jan 5, 2026Bought 775 shares at $35.39 of Indivior⁷
Nov 19, 2021Returned to company 12,631 shares at $8.50 of Flexion Therapeutics⁵

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARIndivior, Board member
2
SEC EDGARFlexion Therapeutics, Board member
3
SEC EDGARAlkermes, Chief Commercial Officer
4
SEC EDGARIndivior shares after the filing of May 13, 2026
5
SEC EDGARFlexion Therapeutics shares after the filing of Nov 19, 2021
6
SEC EDGARForm 4 filed Jan 28, 2026
7
SEC EDGARForm 4 filed Jan 7, 2026